Arch Biopartners Inc V.ARCH

4.04 - Extremely Undervalued in Comparison to peers

[Riverfolk]

The recent realization by the market has made the Arch chart look incredible, but lets no forget that we are extremely undervalued compared to our peer 

Current Market cap 196.5 mil US

We are waiting on Phase II Human Clinical Trial Data by a third party for a 20 billion a year unmet market.

BLU is currently 695 mil market cap for Chronic Cough (Phase 2)

VXRT is currently 888 mil market cap  US Oral Vaccines

SAVA is 2 billion US market cap for Blood Cancer (Phase 2)

CYDY is 1.1  billion US market cap for Antibodies

TRIL was 2.2 billion buyout (Phase 2)

As we wait on data, there is no reason why we are not at a 695 million market cap of $11.20. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

[Antonius2]

100% in agreement plus Arch's "peers" have competition in their respective drug marketplaces - Arch has no meaningful competion in the AKI space.

[Antonius2]

100% in agreement plus Arch@s @peers@ have competition in their respective drug marketplaces - Arch has no meaningful competition in the AKI space.

[wethenorthh]

Totally agree. Guys like Edward Jones going to regret selling their shares for cheap...better for the rest of us I suppose!